1-9 of 9
Catherine Davis, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Stuart L. Goldberg, MD, Michael J. Mauro, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2929.
https://doi.org/10.1182/blood-2019-127959
Published: 2019
Journal Articles

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Ravi Vij, MBBS, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Catherine Davis, PharmD, David J. Kuter, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3284.
https://doi.org/10.1182/blood-2018-99-112074
Published: 2018
Journal Articles

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Gordon Cook, David Cella, PhD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Brian GM Durie, MD, Hartmut Goldschmidt, MD, David J. Kuter, MD, Philippe Moreau, Ravi Vij, MBBS
Journal: Blood
Blood (2018) 132 (Supplement 1): 3285.
https://doi.org/10.1182/blood-2018-99-112081
Published: 2018
Journal Articles

Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Michael J. Mauro, MD, Ginny P Sen, MPH, Srikanth Gajavelli, MD, Catherine Davis, PharmD, Stuart L. Goldberg, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1730.
https://doi.org/10.1182/blood-2018-99-118119
Published: 2018
Journal Articles

Quality of Life During Early Tyrosine Kinase Inhibitor Treatment As Self-Reported by Chronic Myeloid Leukemia Patients Participating in a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, Michael J. Mauro, MD, Stuart L. Goldberg, MD, Ron Paquette, MD, PhD, H. Jean Khoury, MD, FACP, Ishan Hirji, MPH, Samuel Wagner, PhD, RPh, Sam Joo, PhD, Catherine Davis, PharmD
Journal: Blood
Blood (2011) 118 (21): 4435.
https://doi.org/10.1182/blood.V118.21.4435.4435
Published: 2011
Journal Articles

Comparative Efficacy of First Line Treatment of Chronic Myeloid Leukaemia (CML): A Systematic Review and Meta-Analysis.

Stuart Mealing, MSc, Leticia Barcena, Ldo.Vet, Neil Hawkins, PhD, James Clark, MBiochem, Catherine Davis, PharmD
Journal: Blood
Blood (2010) 116 (21): 3436.
https://doi.org/10.1182/blood.V116.21.3436.3436
Published: 2010
Journal Articles

A Disease Model to Predict the Long-Term Outcomes Associated with Treatments for Chronic Myelogenous Leukemia (CML).

Matthew Taylor, PhD, Lily Lewis, BSc, Thomas Patton, MSc, Ishan Hirji, BSP(Pharm), MPH, Catherine Davis, PharmD
Journal: Blood
Blood (2010) 116 (21): 4480.
https://doi.org/10.1182/blood.V116.21.4480.4480
Published: 2010
Journal Articles

Assessing the Experience of Living with Chronic Myeloid Leukemia (CML) From the Patient's Perspective: Results of a Patient Survey

Timothy W Victor, Ph.D., Ishan Hirji, Ian Hicks, Jonathan Chapnick, Catherine Davis, PharmD, Erkut Bahceci, MD
Journal: Blood
Blood (2010) 116 (21): 4755.
https://doi.org/10.1182/blood.V116.21.4755.4755
Published: 2010
Journal Articles

An Economic Evaluation of Dasatinib for the Treatment of Imatinib-Resistant Patients with Chronic Myelogenous Leukaemia.

Matthew J Taylor, Ph.D., Ruth C Saxby, BA(Hons), Catherine Davis, PharmD
Journal: Blood
Blood (2009) 114 (22): 4535.
https://doi.org/10.1182/blood.V114.22.4535.4535
Published: 2009